<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_a_033.html</title>
</head>
<body>
<p>* The company reorganized its business into Kidney Care and HCP divisions.</p>
<p>* A government investigation was finalized, imposing a Corporate Integrity Agreement.</p>
<p>* The settlement requires unwinding certain joint ventures and restricts future transactions.</p>
<p>* Adjusted consolidated operating income decreased, reversing the prior yearâ€™s growth.</p>
<p>* HCP&#x27;s operating income was negatively impacted by reduced Medicare Advantage rates.</p>
<p>* The dialysis segment experienced a significant increase in pharmaceutical costs.</p>
<p>* New government care models, such as ESCOs, were introduced as a risk.</p>
<p>* Future Medicare payment increases will be reduced due to new legislation.</p>
<p>* The primary driver for higher patient care costs shifted to pharmaceuticals.</p>
<p>* Revenue growth was partly driven by recognizing previously reserved state revenue.</p>
<p>* General and administrative expenses decreased, reversing the prior year&#x27;s increasing trend.</p>
<p>* The provision for uncollectible accounts receivable continued to increase.</p>
<p>* Productivity in the dialysis segment is now cited as a positive financial driver.</p>
<p>* Higher pharmaceutical costs negatively impacted dialysis income, a reversal from the prior year.</p>
<p>* A new HCP revenue source from maintaining physician networks is now disclosed.</p>
<p>* The company formed a new major joint venture named Tandigm Health.</p>
<p>* Medicaid expansion is newly cited as a primary driver of HCP membership growth.</p>
<p>* A specific negative financial outlook for future Medicare Advantage rates is now provided.</p>
<p>* HCP administrative spending shifted from cost control to supporting growth and acquisitions.</p>
<p>* Start-up costs from the new joint venture are cited for reduced equity income.</p>
<p>* The company discloses new expenses related to intellectual property and licensing.</p>
<p>* The company executed a major refinancing of its senior credit facilities and notes.</p>
<p>* The company now reports holding significant short-term investments.</p>
<p>* A large legal settlement payment is cited for decreasing operating cash flow.</p>
<p>* The revolving credit facility was substantially increased to $1 billion.</p>
<p>* Previously cited growth drivers for ancillary services are no longer mentioned.</p>
<p>* The company conducted a significant debt refinancing, including repurchasing senior notes.</p>
<p>* Large charges were recorded as a result of debt refinancing activities.</p>
<p>* The interest rate hedging portfolio was significantly restructured.</p>
<p>* The available revolving credit facility was substantially increased.</p>
<p>* A new goodwill impairment risk for the HCP business was disclosed.</p>
<p>* HCP&#x27;s operating results eroded due to lower Medicare Advantage reimbursement rates.</p>
<p>* Certain HCP business units narrowly avoided goodwill impairment charges.</p>
<p>* A new sensitivity analysis for potential goodwill impairment was provided.</p>
<p>* An immaterial goodwill impairment was recorded for international operations.</p>
<p>* Performance-based stock units were introduced to the long-term incentive plan.</p>
<p>* The potential earn-out from the HomeChoice divestiture was significantly reduced.</p>
<p>* New supplemental financial data was disclosed for certain physician groups.</p>
<p>* Forward-looking language about new HCP capitation arrangements was removed.</p>
<p>* Upcoming changes to revenue recognition and discontinued operations accounting were disclosed.</p>
</body>
</html>
